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Abstract 
 
Scope: The intake of sucrose is of public health concern but limited information is available 
on the metabolic effects of short term exposure. Our aim was to use metabolomics to 
investigate the metabolic impact of acute sucrose exposure.  
Methods and results: We performed a randomised, parallel, single-dose feeding study on 
healthy females (n=90, aged 29.9±4.7 yr, BMI 23.3±2.5 kg/m2) consuming either 0g, 50g or 
100g sucrose in 500ml water. Blood and urine samples were taken before and for 24 h post 
sucrose intake. Urine and plasma samples underwent detailed metabolite profiling analysis 
using established protocols. FIE-MS fingerprinting analysis showed that 3 h after intake was 
the most informative time point in urine and plasma and out of 120 explanatory signals, 
highlighted 16 major metabolite signals in urine and 25 metabolite signals in plasma that 
were discriminatory and correlated with sucrose intake over time. The main confirmed 
metabolites positively correlated with intake were sucrose, fructose and erythronic acid, 
while those negatively correlating with intake included fatty acids and derivatives, acyl-
carnitines and ketone bodies. GC-tof-MS profiling analysis confirmed the fingerprinting data. 
Conclusions: Acute exposure to sucrose identified a number of metabolites correlated with 
sucrose intake and several compounds attributed to metabolic fasting. 
 
1. Introduction  
 
Carbohydrates are an important source of energy in the UK population with the 
average contribution to total food energy intake being approximately 48% for adults [1] and a 
current recommendation of 50%. Sucrose is generally obtained from sweetened snacks and 
beverages but a small portion can also be obtained from intrinsic sources such as fruits & 
vegetables [1]. Current average intakes for extrinsic sugars in the UK are 72 g/d and 52 g/d 
for adult men and women, respectively. Recently it is becoming clear that excessive intakes 
of rapidly absorbed added sugars and sugar-sweetened snacks are of health concern and 
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related to negative health effects such as insulin resistance (IR), type 2 diabetes, obesity, 
cardiovascular disease and dental caries [2, 3].  
Recent research has looked at the metabolic consequences of consuming sucrose as whole, 
or its digestion products fructose and glucose [4-6]. Increased fructose and or sucrose intake 
can induce a hyperinsulinaemic state that has prolonged effects on lipid metabolism [7, 8]. 
These studies have shown that fructose consumption, but not glucose consumption, increased 
plasma triglyceride concentrations, increased de novo hepatic lipogenesis, increased 
concentration of smaller dense LDL, and decreased lipoprotein lipase activity. Fructose 
consumption also increased fasting glucose concentrations and decreased insulin sensitivity 
[5, 6, 8]. In studies investigating the effects of glucose on metabolism during an oral glucose 
tolerance test, metabolic changes to a number of pathways in central metabolism including 
proteolysis, lipolysis, ketogenesis and glycolysis were revealed [9-11]. It is clear then that 
consuming sucrose has profound metabolic effects and is of interest to investigate. 
Following sucrose intake it has been shown that there is a time-dependent appearance of 
fructose and sucrose in the urine [12] and urinary sucrose and fructose have been suggested 
as predictive biomarkers for sucrose intake [12-15], which has been recently reviewed [16]. 
Luceri et al [12] found a significant correlation between sucrose intake and both sucrose 
excretion and fructose excretion in spot collections and Tasevska et al [13] found urinary 
excretion of sucrose and fructose to be significantly correlated with sucrose intake in daily 24 
h urine collections under highly controlled conditions, such that 200 g of total sugars intake 
predicted 100 mg sucrose and fructose in the urine [13]. More recently, the same authors 
found that self-reported sugar intake was significantly misreported when using urinary 
sucrose as a biomarker in a larger population [17]. However, although a relationship between 
urinary sucrose excretion and extrinsic sugar intake clearly exists, its use in free-living 
population studies requires calibration equations [18], and it is not clear if this method will be 
able to quantitatively determine intake of these sugars in free-living populations [13, 16] and 
other potential biomarkers of sucrose intake would be interesting to develop. 
There has been an interest in developing metabolomic approaches to monitor dietary intake 
and their effects on metabolism [19, 20]. By virtue of its comprehensive and non-selective 
approach to sample analysis, metabolomic procedures can define metabolic signals indicative 
of dietary exposure not previously considered, and has offered the potential of developing 
biological markers of dietary intake [20-22]. 
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In the current study we have used standardized protocols for metabolite fingerprinting of 
spot urine and plasma samples [21, 23] to investigate the influence of acute sucrose intake on 
metabolite profiles. Our aims overlap and are two-fold; to use metabolomics to firstly explore 
the specific metabolic impact of acute sucrose exposure and secondly to identify metabolites 
that are correlated to sucrose intake that offer potential to be further developed into 
quantitative biomarkers. These are important to establish given the public health interest in 
sucrose intake and to interpret diet-disease associations in population studies. 
 
2. Materials & Methods  
 
2.1 Ethical approval and subject recruitment 
The procedures used were in accordance with the Helsinki Declaration of 1975 as revised 
in 1983. The project was granted ethical approval by the Cambridgeshire 3 Research Ethics 
Committee (ref: 09/H0306/56). Subjects were recruited at two centres, Cranfield University 
and HNR-MRC at Cambridge through advertisement and from previous study databases. 
Volunteers were initially interviewed by phone and assessed for suitability via a screening 
questionnaire relating to their general health and carbohydrate intake.  
Inclusion criteria were female, outwardly healthy and free from prescription medication, 
non-smoking, aged between 25-40, and a BMI between 20 – 30 kg/m2. Exclusion criteria 
included extremes of CHO intake (estimated at <30% or >60% of energy from food diaries 
and specific dietary questions), those taking nutritional supplements in preceding 2 months, 
being pregnant, history of any metabolic disease, recent use of hypolipidemic therapy, 
systemic corticosteroids, or those receiving drugs for regulating haemostasis or chronic 
disease, weight change of >3kg in preceding 2 months, unwilling to follow the protocol 
and/or give informed consent were also excluded. 
 
2.2 Study design 
A randomised, parallel, controlled study, to compare the response of subjects (n=30 per 
group) consuming a test drink containing either 0, 50 or 100 g sucrose in water followed by 
sampling of blood at 0, 3 and 24 h, and urine at 0, 3, 6, 9 and 24 h. We aimed for 30 
individuals for each treatment, 90 were required in total. 
 5
Subjects were provided with standard meals on the evening prior to the study day, at lunch, 
and on the evening of the study day in order to reduce major fluctuations in carbohydrate 
intake and decrease metabolite variability. Each meal contained a relatively low content of 
carbohydrate and no extrinsic sugars. Foods were purchased in bulk from the same 
supermarket to avoid any availability issues. Subjects avoided food & beverages containing 
sucrose for the study period from day 0 until when the 24 h samples were taken.  
On the evening prior to the study, subjects emptied their bladder before eating a standard 
meal of baked salmon fillets with steamed vegetables (carrots, cauliflower and broccoli) (719 
kcal, 68.6 g protein, 45.9 g fat, 9.1 g CHO with 3.6 g as sugars) and collected their urine into 
a suitable container for the rest of the evening, overnight and first void in the morning (1st 
overnight, ON1). Urine was stored in a cool bag with cool packs. Subjects fasted for a 
minimum of 12 hours. On the study day, subjects reported to the Nutrition Unit (at either 
Cranfield or HNR-Cambridge) where they had anthropometric, body composition and blood 
pressure measurements taken and provided a spot urine collection (0 h fasting spot). 
Immediately after subjects provided a fasting baseline blood sample (0 h fasting blood) they 
were given their test drink of 0, 50 or 100 g sucrose in 500 ml water (randomized groups A, 
B and C, respectively). Water was provided by the investigators on the study day (2 x 500 
ml) and the subjects were encouraged to drink throughout the day. At 3 h post consumption 
the subjects were again asked to provide a spot urine collection (3 h spot) and again 
immediately afterwards subjects provided a blood sample (3 h blood). Subjects were 
provided with a standard lunch of baked haddock with steamed vegetables (as above)(496 
kcal, 46.8 g protein, 28.1 g fat, 14.1 g CHO with 6.9 g as sugars). Further spot urine 
collections were taken at 6 hours post (6 h spot), and 9 hours post (9 h spot). Subjects were 
provided with a standard evening meal of grilled chicken with steamed vegetables(as above) 
(599 kcal, 46.6 g protein, 39.1 g fat, 13.8 g CHO with 4.4 g as sugars), before which they 
emptied their bladder and collected their urine for the rest of the evening, overnight and first 
void in the morning (2nd overnight, ON2). Subjects then fasted for a minimum of 12 hours 
and were not allowed any further food or drink (apart from water). Subjects then reported to 
the Nutrition unit at the same time as for the previous day, provided a further fasting spot 
urine collection (24 h fasting spot) and a blood sample (24 h blood). No other food and drink, 
other than that provided by the investigators, was consumed during the study period. 
 
2.3 Anthropometric measurements and Dietary anaylsis 
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Height was measured using a wall mounted Stadiometer. A Tanita™ segmental body 
composition analyser (BC-418) was used to assess body composition (% body fat, BMI and 
weight) immediately after measurements of height. Subjects removed their socks and shoes 
prior to recording and a researcher ensured that the subjects were standing correctly on the 
pads and holding the handheld pads required for full assessment. Measurements were taken 
on the morning of the study day in a fasted state. Blood pressure was measured using a 
handheld electronic device. Subjects were allowed to rest for 5 minutes before measurements 
were taken and triplicate measurements were taken over a 5 minute period and averaged. 
Subjects were monitored for their habitual food intake prior to the trial using a 4-day food 
diary which ended on, and included, the day before the trial (day 0). The food diary was pre-
validated, developed by the MRC-HNR at Cambridge. The food diaries were converted to 
macro and micronutrient intake using the Dietplan 6 software package (Forestfield Software 
2008), which utilizes food composition tables from McCance and Widdowson [24], and with 
additional information from food manufacturers and recipe analysis. Dietary analysis was co-
ordinated and performed by the dietetic group in the Division of Nutritional Sciences, 
University of Surrey. 
 
2.4 Biological sample collection 
Blood was taken by a suitably trained person using the Sarstedt Monovette system. On 
each occasion blood was drawn into 2 x 8 ml lithium heparin (Li/Hep) tubes and centrifuged 
(3500 rpm at 10˚C for 15 min) exactly 15 min following blood collection. Aliquots of plasma 
from each of these tubes were immediately frozen (liquid N2) and stored at -80˚C prior to 
processing and analysis. Aliquots from each of the Li/Hep tubes were used as analytical 
replicates.  
Urine was collected into suitable containers and stored under refrigerated conditions (or in 
a cool bag with cool packs when subjects were not on site). Following the final collection, 
volumes were recorded and aliquots were taken and frozen. Samples were stored at -80˚C 
prior to processing and analysis. 
 
2.5 Clinical Biochemistry measures 
Plasma glucose, triglycerides, total cholesterol, HDL and LDL cholesterol were measured 
from 1 ml Li/Hep aliquots by standard enzymatic assays on a clinical analyser at the Core 
Biochemical Assay Laboratory (CBAL) at Addenbrooke’s Hospital, Cambridge. Insulin and 
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C-peptide were measured from the same 1 ml aliquots by immunoassay by the CBAL. 
Urinary creatinine and the electrolytes sodium, potassium and chloride were measured in 
reconstructed 24 h urine collections from the study day by standard assays and also by the 
CBAL. 
 
2.6 Metabolomic sample preparation  
Biological samples were prepared as previously described [21, 22]. Briefly, plasma (200 
µL) was extracted in a 2.0 mL glass beads-containing Eppendorf tube in 1520 µL at -20 °C 
pre-chilled methanol/CHCl3 (4:1) using a mixer-mill (MM300, Retsch) for 30 sec at 30 Hz, 
vortexed, stored at -20 °C in a freezer for 20 minutes, shaken for 15 min at 4 °C and then 
centrifuged for 6 min at 4 °C and 13,000 rpm (Biofuge fresco, Hareaus). For FIE-MS and 
GC-tof-MS analysis 100 µL and 420 µL supernatant was dried respectively in vacuo (speed-
vac, Univapo). Urine samples (50 µL) were diluted with 450 µL of pre-chilled 
methanol/water (3.5:1), vortexed and shaken and centrifuged as for plasma. For GC-tof-MS 
analysis 300 µL supernatant was dried in the speedvac and derivatised according to [21, 22]. 
Extracts and dried samples were stored at -80 °C until required. For FIE-MS analysis, plasma 
samples were reconstituted in 100 uL Methanol/H2O 70/30, urine samples were used directly.  
 
2.7 Metabolite fingerprinting and profiling 
Urine and plasma samples were analyzed separately in randomized batches. All biological 
samples of a biofluid were analyzed in a hierarchical approach as reported previously [21]. 
FIE-MS fingerprinting on an LTQ linear ion trap (Thermo Electron Corporation) was 
followed by in-depth uni- and multivariate supervised and non-supervised data analysis and 
feature selection tools using the FIEmspro workflow (R-package available at: 
http://users.aber.ac.uk/jhd/) [25] as described in detail elsewhere [22]. The identity of 
potential discriminatory ions (m/z) was investigated by analysis of selected nominal mass 
bins in pooled samples using targeted nano-flow Fourier-Transform ion cyclotron resonance 
Mass Spectrometry (FT-icr-MS) using a TriVersa NanoMate (Advion BioSciences Ltd) on a 
LTQ-FT-ULTRA (Thermo Scientific) to obtain ultra-high accurate mass information and 
MSn ion-trees [22]. These accurate masses were subsequently used to search the LC-MS 
annotation database MZedDB. Metabolite profiling by GC-tof-MS was undertaken to identify 
further sucrose responsive metabolites not detected well by FIE-MS and to confirm results of 
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putative assignments. GC-tof-MS profiling on Pegasus III (Leco Inc) and subsequent data 
analysis was carried out as reported recently [22].  
 
2.8 Statistical analysis 
To test for the effects of time and treatment on clinical markers either 1-way or 2-way 
Analysis of Variance (ANOVA) was used depending on the appropriate test required. 
Pearsons correlations between variables from specific time points in each treatment group 
were also assessed. For metabolite fingerprinting analysis samples were subjected to 
unsupervised and supervised multivariate classification using Principal Components Analysis 
(PCA) and PC-Linear Discriminant Analysis (PC-LDA), respectively. Classification and data 
mining was carried out by following the FIEmspro workflow validated previously by 
Aberystwyth [25] (http://users.aber.ac.uk/jhd/). Eigenvalues (Tw), Classification accuracies 
and Random Forest (RF) ‘margins’ between data models were calculated to provide metrics 
of similarity. Classification accuracies in excess of 95% with model margins > 0.2 or 
Eigenvalues > 1.5 in such pair-wise comparisons were taken as evidence of adequate 
differences. Feature selection techniques were used as described  previously [26] to highlight 
the potentially explanatory mass signals responsible for discriminating between different 
dietary exposure level classes. For GC-tof-MS data filtering purposes metabolite signals with 
P>1x10-4 following all pair-wise comparisons of the different sample classes were removed 
from the data set. 
 
3. Results  
 
3.1 Volunteer baseline characteristics and dietary analysis 
Table 1 shows the subject characteristics at baseline prior to the sucrose intervention. There 
were no significant differences between any of the variables between groups. There was a 
relatively low SD in age, BMI, average sucrose intake and total carbohydrate intake, and 
normal electrolyte excretion, glucose control and lipid status parameters. 
 
3.2 FIE-MS sample classification to detect metabolites associated with acute sucrose 
exposure 
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Principal Components Linear Discriminant Analysis (PC-LDA) was performed on FIE-MS 
data in 100 m/z ranges. Class discrimination was visualized in PC-LDA score plots, with Tw 
values of the adequate models in urine (Fig. 1A) and plasma (Fig. 1B), showing 
discrimination between the three treatment groups. In urine, discrimination was strongest for 
m/z-ranges 201-400 in positive and 101-400 in negative ionisation mode at the 3 h time-point 
(Tw >2), with poor models (Tw <1.5) found in all other time points. In plasma, 
discrimination was strongest for m/z-ranges 101-400 in positive and 101-400 in negative 
ionisation mode also at the 3 h time-point. Only these models were pursued further in terms 
of feature selection.  
 
 
Table 1. Baseline characteristics and dietary intake of all subjects 
     
  Treatment group 
 Total group 0 g 50 g 100 g 
     Volunteers [n]  97 35 31 31 
Age [y] 29.9 ± 4.7 29.8 ± 4.4 30.5 ± 5.2 29.1 ± 4.1 
BMI [Kg/m2] 23.3 ± 2.5 23.1 ± 5.4 23.1 ± 2.3 23.6 ± 2.9 
Body fat [%] 30.1 ± 5.3 29.6 ± 5.1 30.2 ± 5.7 30.4 ± 5.1 
Systolic BP [mmHg]  115 ± 12 113 ± 12 113 ± 11 118 ± 11 
Diastolic BP [mmHg] 70 ±7 72 ± 8 69 ± 7 69 ± 7 
Dietary intake:     
Energy [kcal] 1854 ± 427 1838 ± 410 1849 ± 410 1875 ± 474 
Protein [g]  75 ± 20 74 ± 18 74 ± 19 76 ± 22 
Fat [g] 73 ± 24 71 ± 26 75 ± 23 75 ± 23 
Alcohol [g] 11 ± 17 9.6 ± 20.5 12 ± 15 10 ± 16 
Carbohydrate [g] 204 ± 50 209 ± 49 198 ± 45 206 ± 58 
Total sugars [g] 86 ± 31 84 ± 29 82 ± 26 93 ± 37 
Sucrose [g] 35 ± 14 35 ± 13 31 ± 13 38 ± 17 
Fructose [g] 18 ± 9 16 ± 7 18 ± 11 19 ± 10 
Glucose [g] 16 ± 8 15 ± 6 16 ± 10 16 ± 8 
Electrolytes:     
Na+ [mmol/L] 44.4 ± 19.1 47.3 ± 19.2 42.8 ± 19.8 42.5 ± 18.5 
K+ [mmol/L] 22.0 ± 8.6 23.3 ± 6.9 19.1 ± 8.3 23.4 ± 10.1 
Cl– [mmol/L] 48.5 ± 19.6 50.7 ± 19.1 45.6 ± 19.2 48.9 ± 20.8 
Creatinine [mmol/L] 5.8 ± 2.4 6.11 ± 2.3 5.0 ± 2.3 6.4 ± 2.6 
Glucose control:     
HOMA [IR] 7.3 ± 3.6 7.6 ± 3.7 7.0 ± 2.9 7.5 ± 4.1 
HOMA [%B] 489 ± 217 481 ± 225 535 ± 223 449 ± 181 
Glucose [mmol/L] 4.89 ± 0.3 4.96 ± 0.4 4.75 ± 0.3 4.95 ± 0.3 
Insulin [pmol/L] 33 ± 15 34 ± 16 32 ± 13 33 ± 17 
Lipid status:     
Triglycerides [mmol/L] 0.84 ± 0.30 0.79 ± 0.33 0.81 ± 0.29 0.91 ± 0.26 
Total Cholesterol [mmol/L] 4.53 ± 0.70 4.51 ± 0.74 4.47 ± 0.65 4.62 ± 0.72 
 10
LDL-Cholesterol [mmol/L] 1.76 ± 0.32 2.33 ± 0.49 2.39 ± 0.47 2.45 ± 0.58 
HDL-Cholesterol [mmol/L] 2.39 ± 0.51 1.80 ± 0.39 1.72 ± 0.29 1.75 ± 0.27 
 
 
 
 
 
 
A Urine 
B Plasma 
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Figure 1. Comparison of sucrose treatment groups by Flow-Injection Electrospray Mass 
Spectrometry (FIE-MS) fingerprinting of 3 h (a) urine and (b) plasma samples:  Principal 
Components Linear Discriminant Analysis score plots of Discriminant Function 1 (DF1) and 
DF2 for informative FIE-MS mass ranges in both positive (p) and negative (n) ionization 
modes. Subjects grouped as A (0 g sucrose, control), B (50 g sucrose) and C (100 g sucrose).  
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3.3 Selection of metabolome features explanatory of acute sucrose exposure 
RF importance scores highlighted around 120 important m/z values in both plasma and 
urine that differed in intensity between treatment groups. From this list the top ranked 
variables in urine (16 metabolites) and plasma (24 metabolites) underwent putative 
identification and correlation analysis to give more insight into trends of metabolite 
behaviour as a response to the different levels of sucrose treatment. 
Correlation analysis of these major discriminatory ions are shown in Figure 2A and B for 
urine and plasma respectively. In urine the features are split between those that are positively 
and negatively correlated with sucrose intake (Figure 2A). The variable m/z n215.18 was the 
overall strongest discriminator (Rank 1), but only important in 3 h data whereas other 
variables were discriminatory at two consecutive time points (3 h and 6 h e.g. m/z n135.18, 
p381) and were highly correlated. The highest ranked negatively correlated ion was m/z 
n139.18 which was highly correlated with m/z n161.18 and n101.18 but the latter were less 
highly ranked than the other variables in urine.  
In plasma, signals are split into two main clusters (Figure 2B): one with a strong positive 
correlation with sucrose intake (Clade 1) and a second divided into different levels of 
negative correlation with sucrose intake (Clades 2 to 4).  The most highly ranked signal that 
was positively correlated with sucrose intake was m/z n263.18 and n207.18 that were highly 
correlated. The most highly ranked variables were negatively correlated with sucrose intake 
and appeared in Clade 4 (e.g. m/z n130.27, p154.18, n129.27).  
 
3.4 Annotation of discriminatory signals and relative intensities with sucrose intake 
Signals suggested by the MZedDB were confirmed using GC-tof-MS and comparison with 
standards. Some of the FIE-MS nominal mass bins contained up to 10 accurate mass ions in 
FT-icr-MS spectra, some of which did not result in a hit from MZedDB. However, the list of 
discriminatory variables was dominated by organic acid or fatty acids isomer putative 
assignments. Many of the explanatory plasma signals were highly correlated and so are 
grouped into Clades in Table 2 which helps to determine signal relationships. For example, 
whereas metabolites in Clade 2 were mainly free fatty acids, Clade 3 contains the main 
ketone bodies, acetoacetone and 3-hydroxybutanoic acid. Clade 4 contains metabolites 
associated with branched chain amino acids metabolism. Several signals were found highly 
discriminatory in both the urine and plasma data. These included n101.27 (acetoacetate), and 
n139.27 (octadienoic acid), both negatively correlated with sucrose intake (Figure 2).  
 
 13
 
Figure 2. Hierarchical cluster analysis of Log10-transformed and TIC-normalized intensity 
values of putative metabolites discriminating between sucrose treatments in (A) 3 h urine (B) 
3 h plasma samples with ions representing positive (p) and negative (n) ionisation mode 
features. 
 
The signals n135.18 (urine) and n135.27 (plasma) that were positively correlated with 
sucrose intake (Figure 2) were assigned as erythronic acid. The identity of erythronic acid 
was confirmed by comparing retention time characteristics of erythronic acid standards with 
threonic acid with those observed in plasma GC-tof-MS data and those reported in the Golm 
Metabolite Data base [27].  
 
Examples of relative intensity distributions of highly ranked variables between particular 
treatment groups and specific time points in urine data are shown in Figure 3. The left panel 
shows three signals most strongly positively correlated with sucrose intake. The chloride 
adduct of fructose was only explanatory in 3 h urine samples, whereas the potassium adduct 
of sucrose was discriminatory at the 6 h time point. The signal intensities of negatively 
correlated explanatory mass ions show the opposite trend (right panel in Figure 3); with 
metabolites found at higher levels in urines of those volunteers in the 0 g sucrose group. In 
the examples shown (hydroxybutanoic acid acid, acetyl carnitine, and tridecanedionic acid) 
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the differences between treatment groups were highly significant still at 9 h. In these 
examples the highest sucrose dose showed the least increase in metabolite levels. 
Examples of relative intensity distributions of highly ranked variables in plasma data are 
shown in Figure 4. The left hand panel shows the levels of three example m/z ions which 
demonstrated a positive correlation with sucrose treatment from Clade 1 (Table 2). 
Intensities of these positively correlated metabolites were significantly increased at the 3 h 
time point in the 50 g and 100 g groups, and the intensity had returned to baseline after 24 h.  
The opposite trend was seen in those signals negatively correlated with sucrose intake, 
examples of which are shown in the right panel of Figure 4. In these signals from Clade 4 
(Table 2) the intensity at 3 h was lower than at baseline in the 50 g and 100 g groups, 
however in the 0 g group intensities appeared to increase up to 24 h later and significant 
effects were observed at both 3 h and 24 h.  
 
 
 
Table 2. Tentative identity of highly ranked urine and plasma signals potentially explanatory 
of acute dietary sucrose exposure using Fourier Transform-Ion Cyclotron Resonance Ultra-
Mass-Spectrometry (FT-icr-MS). Flow-Injection Electrospray Mass Spectrometry (FIE-MS) 
mass ions are listed in the order as shown in Figure 2A and 2B, respectively.  Listed are only 
those accurate masses which resulted a hit in MZedDB. The dominant accurate mass ion is 
printed in bold.  
Rank§ FIE-MS FT-MS[m/z] Adduct – Adduct Potential Metabolites* 
 Urine      
 Positively correlated  
4 p365.18 365.10544 C12H22NaO11 [M+Na]1+ Sucrose* (and other disaccharides) 
2 p381 381.07937 C12H22KO11 [M+K]1+ Sucrose* (and other disaccharides) 
12 n377.09 377.08562 C12H22ClO11 [M+Cl]1- Sucrose* (and other disaccharides) 
7 n341.09 341.10894 C12H21O11 [M-H]1- Sucrose* (and other disaccharides) 
1 n215.18 215.03288 C6H12ClO6  [M+Cl]1- Fructose* (and hexose isomers) 
6 n135.18 135.03003 C4H7O5  [M-H]1- Erythronic acid*  
 Negatively correlated 
16 n161.18 161.04567 C6H9O5  [M-H]1- Hydroxyl-hexanedioic acid 
14 n101.18 101.02448 C4H5O3  [M-H]1- Acetoacetate (and isomers) 
3 n139.18 139.07655 C8H11O2  [M-H]1- Octadienoic acid (and isomers) 
  139.01676 C4H8ClO3  [M+Cl]1- 3-Hydroxybutanoic acid* 
10 p204.09 204.12320 C9H18NO4 [M+H]1+ Acetylcarnitine  
   
C9H18NO4 [M1+.]1+ O-Acetylcarnitine 
13 n241.18 241.11936 C11H17N2O4 [M-H]1- Unknown  
  
241.21728 C15H29O2  [M-H]1- Pentadecanoic acid (and isomers) 
11 n243.18 243.06224 C9H11N2O6  [M-H]1- Uridine  
  243.13501 C11H19N2O4 [M-H]1- Unknown  
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Rank§ FIE-MS FT-MS[m/z] Adduct – Adduct Potential Metabolites* 
 Plasma      
 Positively correlated Clade 1  
7 n207.18 207.07939 C9H16ClO3  [M+Cl]1- Keto-nonanoic acid (and isomers) 
  
207.11582 C10H20ClO2  [M+Cl]1- Decanoic acid*  
6 n263.18 263.12879 C15H19O4  [M-H]1- Unknown 
23 n135.27 135.02999 C4H7O5  [M-H]1- Erythronic acid*  
14 n125.27 125.00113 C3H6ClO3  [M+Cl]1- Lactic acid 
8 n205.18 205.14464 C10H21O4 [M-H]1- Unknown 
  
205.06371 C9H14ClO3  [M+Cl]1- 2-Butyl-4-hydroxy-5-methyl-3(2H)-
22 p135.09 135.08043 C9H11O  [M+H-FA]1+ 10-hydroxy-2E,8Z-Decadiene-4,6-
15 n147.18 147.02999 C5H7O5  [M-H]1- Methylmalic acid 
  147.06637 C6H11O4  [M-H]1- 2,3-Dihydroxy-3-methylpentanoate  
21 p193.09 193.12240 C12H17O2  [M+H]1+ Dodecatetraenoic acid 
  193.14351 C9H21O4 [M+H]1+ Unknown 
 Negatively correlated Clade 2  
18 n277.18 277.18087 C17H25O3  [M-H]1- Hydroxy-heptadecadien-ynoic acid; 
  
277.21722 C18H29O2  [M-H]1- Octadecatrienoic acid; linolenic acid  
10 n315.27 315.20956 C18H32ClO2  [M+Cl]1- Octadecadienoic acid 
  315.25398 C18H35O4  [M-H]1- Dihydroxy-octadecanoic acid 
9 n253.45 253.21720 C16H29O2  [M-H]1- Hexadecenoic acid  
13 n537.27 537.04643   No hit 
 Negatively correlated Clade 3  
17 n103.27 103.04011 C4H7O3  [M-H]1- 3-Hydroxybutanoic acid* 
4 p149.09 149.11726 C7H17O3 [M+H]1+ Unknown 
24 n101.27 101.02448 C4H5O3  [M-H]1- Acetoacetate* (and isomers);  
16 n141.18 141.01704 C4H6NaO4  [M+Na-2H]1- Dihydroxybutanoic acid* 
11 n139.27 139.07655 C8H11O2  [M-H]1- Octadienoic acid (and isomers) 
  139.01676 C4H8ClO3  [M+Cl]1- 3-Hydroxybutanoic acid* 
12 p207.09 207.17449 C14H23O  [M+H-FA]1+ Tetradecadienoic acid 
 Negatively correlated Clade 4 
3 n129.27 129.05579 C6H9O3  [M-H]1- 3-Methyl-2-oxopentanoic acid 
1 n130.27 130.08744 C6H12NO2  [M-H]1- Iso-leucine (and isomers) 
19 p176.18 176.10706 C11H14NO [M+H]1+ Unknown 
5 p175.18 175.09654 C8H15O4  [M+H]1+ Octenedioic acid (and isomers) 
  
175.13291 C9H19O3  [M+H]1+ Hydroxyl nonanoic acid 
2 p154.18 154.08379 C6H13NNaO2 [M+Na]1+ Iso-leucine (and isomers) 
  
154.05865 C4H9N3NaO2 [M+Na]1+ Creatine  
#
 Metabolites found in the same correlation cluster are grouped by clade (Figure 2).   
* Identity of discriminatory metabolites confirmed by GC-tof-MS analysis. 
§  Rank based on Random Forest importance scores. 
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Figure 3. Examples of Log10-transformed and TIC-normalised intensity values of m/z 
variables that discriminate for sucrose treatment in urine samples: repartitioning of urine FIE-
MS data by meta-class sampling time and treatment. Left panel, positively correlated with 
sucrose intake; right panel, negatively correlated with sucrose intake. Sampling times post 
sucrose intake are shown; ON, overnight urine collections; F, fasting; R, reconstituted 24 h 
urine sample. 
 
3.5 GC-tof-MS profiling  
PC-LDA of urine GC-tof-MS data showed very good discrimination (DF1, Tw=9) between 
treatment at the 3 h time point, but in plasma, the 3 h time point provided only an adequate 
model (DF1, Tw=3.65). In urine, the list of explanatory metabolites was extremely short and 
the intensity profiles of the 4 main discriminatory metabolites are shown in Figure 5.  At the 
3 h time point sucrose and fructose strongly discriminate treatment groups in urine samples, 
being positively correlated with sucrose intake. Sucrose was still explanatory for treatment 
differences in 9 h samples. The metabolites 3-amino-2-methyl-propanoic acid and 3-hydroxy-
butanoic acid showed the opposite trend as the intensities consistently remained lower in the 
100 g group and negatively correlated with sucrose intake at 3 h.  
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.011
0.0115
0.012
0.0125
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.009
0.0095
0.01
0.0105
0.011
0.0115
Sucrose m/z 381
Erythronic acid m/z 135.18
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.0105
0.011
0.0115
0.012
0.0125
Fructose m/z 215.18
Lo
g1
0-
tr
an
sf
o
rm
ed
 
an
d 
No
rm
al
iz
ed
 
In
te
n
si
ty
ON1      F0h 3h         6h         9h      ON2    F24h     R24
0 g sucrose 100 g sucrose
0.0106
0.0108
0.011
0.0112
0.0114
0.0116
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.0095
0.01
0.0105
0.011
0.0115
0.012
0.0125
0.013
0.0135
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.0098
0.01
0.0102
0.0104
0.0106
0.0108
0.011
0.0112
0.0114
Hydroxybutanoic acid  m/z 139.18
Acetyl-carnitine m/z 204.09
N1A N1B N1C F1A F1B F1C 3hA 3hB 3hC 6hA 6hB 6hC 9hA 9hB 9hC N2A N2B N2C F2A F2B F2C 24A 24B 24C
0.0104
Tridecanedioic acid m/z 243.18
ON1      F0h 3h         6h         9h      ON2    F24h     R24
 17
 
 
Figure 4. Examples of Log10-transformed and TIC-normalised intensity values of m/z 
variables that discriminate for sucrose treatment in plasma samples: repartitioning of urine 
FIE-MS data by meta-class sampling time and treatment. Left panel, positively correlated 
with sucrose intake; right panel, negatively correlated with sucrose intake. Sampling times 
post sucrose intake are shown; F, fasting. 
 
In plasma (data not shown), results mirrored that from FIE-MS in that sucrose, fructose, 
erythronic acid and one unknown metabolite (characterised by m/z 163, 214, 233, 304), were 
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positively correlated with sucrose intake while metabolites including acetoacetic acid, two 
hydroxy-butanoic acid isomers, 3-amino-2-methyl-propanic acid and eight free fatty acids 
(saturated and unsaturated), were negatively correlated with sucrose intake and showed 
similar relative intensity distributions. 
 
 
4. Discussion  
 
In this study we have investigated the influence of acute sucrose intake on urinary and 
plasma metabolite profiles using metabolomics with the aim of understanding the metabolic 
impact of acute sucrose intake and identifying metabolites with the potential to be developed 
into biomarkers of sucrose intake. This study is novel in that it is the first to use a range of 
non-targeted MS-based technologies and the first to examine both urine and plasma 
metabolomes following acute exposure to sucrose at intakes commonly observed in the 
average UK population. We demonstrate here that sucrose ingestion has influenced 
metabolism with over 120 metabolites in both urine and plasma that discriminated between 
sucrose treatments resulting in differing responses to sucrose intake. We have shown that a 
number of metabolites are directly related to sucrose intake; specific metabolites positively 
correlated to sucrose intake and that have not been previously identified could be developed 
further into biomarkers, metabolites that are increased in intensity but not correlated to 
sucrose intake appear to be in response to the ingestion of water, and those that are negatively 
correlated to sucrose intake and dominant in the control group appear to be due to an overall 
fasting response and metabolic switch from fasting to the fed state.  
 
4.1 Influence of sucrose intake on metabolism 
As would be expected [13, 28, 29], we found sucrose and fructose as responsive features in 
both plasma and urine (Figures 3 & 4). Sucrose is commonly found in the urine of individuals 
due to the inefficiency of sucrase enzymatic cleavage. It is thought that the majority of 
plasma sucrose is excreted in the urine [30], however there is little understanding of plasma 
sucrose kinetics and tissue uptake as the dose-responsive kinetic nature of sucrose/fructose in 
plasma has not been fully explored in previous studies. The urinary excretion profiles of 
sucrose and fructose were different. Fructose demonstrated a maximum excretion only at 3h, 
whereas for sucrose raised levels were evident at extended time points (6h and 9h post).  
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Figure 5. Log10-transformed intensity values of sucrose, fructose, 3-amino-2-methyl-
propanoic acid and 3-hydroxy-butanoic acid discriminating between sucrose treatment: 
repartitioning of urine  Gas Chromatography –time-of-flight - Mass Spectrometry (GC-tof-
MS) data by meta-class sampling time and treatment. Sampling times post sucrose intake are 
shown; ON, overnight urine collections; F, fasting; R, reconstituted 24 h urine sample. 
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This would be expected given the differences in metabolic fate between sucrose and fructose. 
The rapid removal of fructose from the plasma and the low abundance of fructose in 3h 
plasma samples highlights rapid fructose metabolism. The pharmacokinetics of plasma 
fructose following either sucrose or HCFS intake found a Tmax of 60 min and by 180 min 
the concentration had returned to baseline [29].  The metabolic fate of sucrose in plasma is 
unknown.. As we observed a more persistent appearance of sucrose in the urine over the 
course of the day (Figure 3) we can speculate that there is limited transport into cells and 
sucrose is gradually filtered into the urine. The observation that sucrose and fructose were not 
as explanatory in plasma compared to urine suggests that sucrose is removed efficiently from 
blood and excreted; our urine data suggest that sucrose has a half-life of about 3 hours.  
Erythronic acid (2,3,4-tri-hydroxybutyric acid) also demonstrated a positive correlation 
with sucrose intake in both urine and plasma (Figs 3 & 4), and this is the first study to 
demonstrate this link. This sugar can be formed through Maillard reactions fragmenting sugar 
moieties [31]. Erythronic acid is normally found in low concentrations in both urine and 
plasma, but is increased in situations where the flux through the pentose phosphate pathway 
is disturbed [32]. This would lead to an accumulation of metabolites and flux through 
alternative pathways that result in the formation of increased amounts of erythronic acid [32]. 
It is an interesting observation that sucrose intake could potentially cause this effect and one 
that has not been previously observed in humans and could contribute further to the 
metabolic dysregulation induced by excess fructose.  
 
 
Table 3. Summary of fatty acid derivatives negatively correlated with sucrose intake 
putatively identified in plasma and urine signals from FIE-MS and GCMS. 
Carbon backbone NEFA Carnitine derivative 
C8 C8:1 
C8:2 
C8:0 
C9 C9:0  
C10 C10:0 C10:0 
C12 C12:4 C12:0 
C13 C13:2  
C14  C14:1 
C15 C15:0  
C16 C16:1  
C18 C18:1 
C18:2 
C18:1 
C18:2 
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There were further signals that were positively correlated with sucrose intake, but were not 
in the top ranked metabolites investigated further, and these could indicate other metabolic 
pathways influenced by sucrose. For example, m/z n147.18 in plasma could potentially be a 
lactone intermediate from the pentose phosphate pathway or methylmalonic acid, an 
important intermediate in fat and protein metabolism; both of which would align with 
biochemical pathways shown to be influenced in the current study.  
Urinary data over time revealed a number of metabolites with a common profile over time 
that were increased in intensity during the intervention in all groups indicating that the 
response was not dependent on sucrose intake, and therefore they were not investigated 
further. In these examples (data not shown), it is likely that the sudden influx of fluid 
following fasting cased a release of accumulated metabolites into the plasma and rapid 
clearance by the kidney. 
Plasma and urine data demonstrated a number of metabolites that were negatively 
correlated to sucrose intake and were increased in intensity in the control group that received 
only water, but were lower in groups ingesting sucrose (Figs 3 & 4). This group of 
metabolites include a range of free fatty acids, acyl-carnitines and ketone bodies and 
represent classical markers of a fasting response. This fasting response is somewhat 
understandable given the study design, in that subjects in the control group received zero 
calories until their standard lunch (496 kcal), 4-5 hours following the ingestion of 
sucrose/water.  
From FIE-MS and GC-tof-MS analysis we found fatty acyl moieties, either NEFA or 
carnitine derivatives, from 10 separate carbon backbones ranging from medium (C8) to long 
chain (C18) and a mix of saturated and unsaturated (Table 3). NEFA have previously been 
shown to be raised during the fasting state, in which fatty acids are mobilised to act as an 
energy source via -oxidation [33]. It has been shown that fructose intake has a lipogenic 
effect and raises plasma triglycerides [5], however we did not observe such lipogenic effects 
in the present study. Therefore an acute dose of up to 100 g sucrose does not increase NEFA 
or triglycerides in the 24 h timeframe of the current study, and this is an important 
observation. We observed at least 5 differing acyl (fatty acid)-carnitine moieties with varying 
fatty acid chain length and saturation negatively correlated to sucrose intake (Table 3). Acyl-
carnitines, substrates for fatty acid -oxidation, are present during fasting [33] and have also 
been observed during an OGTT [10, 11]. Ketone bodies such as 2-hydroxybutyrate, 3-
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hydroxybutyrate, acetoacetate and acetone have been found as biomarkers of fasting in a 
metabolomic approach [33] and shown to decrease in response to glucose [11].  In the current 
study we observed ketone bodies increasing in intensity with time during the day and 
negatively correlated to sucrose intake (e.g 3-hydroxybutanoic acid in urine and acetoacetate 
in plasma, Fig 3). We also found leucine/isoleucine as a discriminatory metabolite in plasma 
and 3-amino-2-methyl-propanoic acid in urine that were negatively correlated with sucrose 
intake. Amino acids and branched chain amino acids, such as leucine/isoleucine and keto-
amino acid derivatives, have been identified as novel biomarkers of fasting [33]. Intensities 
of these amino acids were raised in baseline samples, and increased during the day in the 
control group that received no sucrose.    
Although this fasting effect is not directly related to sucrose intake it is interesting that we 
can still observe dose-responsive relationships to sucrose ingestion, and this finding that 
differing aspects of the fasting response are related to the level of sucrose intake is novel. For 
example the observation that ketone bodies and acyl-carnitines were not increased in the 
groups receiving sucrose indicates that 50 g sucrose (200 kcal) was sufficient to prevent 
ketosis and mitochondrial fatty acid oxidation. It is also interesting to note that some fasting 
markers continued to increase in intensity during the study day (e.g Figure 3; acetyl-carnitine, 
hydroxybutanoic acid) while NEFA were increased only after 3 h (e.g Figure 3; 
tridecanedioic acid). These observations are of interest in determining the amount of calories 
required to prevent certain metabolic pathways involved in the fasting response but require 
further work to characterise. 
 
4.2 Putative biomarkers of sucrose intake.  
As we have mentioned, those metabolites that are positively correlated to sucrose intake 
are candidates as biomarkers of sucrose intake. Urinary sucrose and fructose, which were the 
highest ranked variables, have been previously suggested as predictive biomarkers for 
sucrose intake [13, 16]. Although a clear relationship between sucrose intake and urinary 
fructose/sucrose existed in various studies [12, 13], the authors highlight that it is not clear if 
these biomarkers could be used to assess sugar intake in larger population studies, and other 
biomarkers are required. The most promising biomarker candidate from the present study is 
erythronic acid, which has not previously been linked to sucrose intake. This was in the top 
ranked variables, positively correlated to sucrose intake, and dose-responsive in urine and 
plasma. We suggest that erythronic acid, alone or in combination with urinary fructose and/or 
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sucrose, could be developed further into a biomarker for sucrose intake, but further studies 
are essential to validate and substantiate these findings. 
In summary, we have demonstrated that specific metabolites can be used to follow 
metabolic changes due to acute sucrose intake in metabolite profiles of plasma and urine, 
many of which have not been observed previously. It is clear from the type of metabolites 
correlated with sucrose intake that a number of biochemical pathways were influenced in our 
intervention but it is difficult to completely understand the metabolic effects of sucrose when 
various metabolic changes are occurring simultaneously by different stimuli in the same 
intervention. We have shown metabolic changes due to the onset of a switch in metabolism 
as a response to the overnight fast coupled with consuming only water, in the presence of 
NEFA, acyl-carnitines and ketone bodies. We suggest that the metabolites that are positively 
correlated to sucrose intake such as erythronic acid, fructose and sucrose, alone or in 
combination, could be investigated further for diagnostic potential as biological markers for 
sucrose intake.  
 
Acknowledgements 
We thank the volunteers that participated in the study. JKL, GF, MEB and JHD designed 
the research. AMJ, MMC and OM conducted research; co-ordinated the human intervention 
trial and collected samples. KT and AJL conducted research; metabolomic analysis of 
samples. BE analyzed dietary data, KT, AJL and MEB analyzed metabolomic data and 
performed statistical analysis. JKL, MEB, GF and JHD wrote the paper. The authors declare 
no conflicts of interest. This work was funded by the UK Department of Health and the Food 
Standards Agency, Project No 024/0044.  
 
Conflict of Interest 
The authors declare no conflicts of interest. 
 
5. References  
[1] Bates, B., Lennox, A., Bates, C., Swan, G., in: Health, D. o. (Ed.), London 2010, p. 
http://www.food.gov.uk/multimedia/pdfs/publication/ndnsreport0809.pdf2010. 
 24
[2] Lofgren, I. E., Herron, K. L., West, K. L., Zern, T. L., et al., Carbohydrate intake is 
correlated with biomarkers for coronary heart disease in a population of overweight 
premenopausal women. J Nutr Biochem 2005, 16, 245-250. 
[3] Mann, J., Cummings, J. H., Englyst, H. N., Key, T., et al., FAO/WHO scientific update 
on carbohydrates in human nutrition: conclusions. Eur J Clin Nutr 2007, 61 Suppl 1, S132-
137. 
[4] Cox, C. L., Stanhope, K. L., Schwarz, J. M., Graham, J. L., et al., Circulating 
Concentrations of Monocyte Chemoattractant Protein-1, Plasminogen Activator Inhibitor-1, 
and Soluble Leukocyte Adhesion Molecule-1 in Overweight/Obese Men and Women 
Consuming Fructose- or Glucose-Sweetened Beverages for 10 Weeks. The Journal of 
clinical endocrinology and metabolism 2011. 
[5] Stanhope, K. L., Bremer, A. A., Medici, V., Nakajima, K., et al., Consumption of fructose 
and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and 
apolipoprotein-B in young men and women. The Journal of clinical endocrinology and 
metabolism 2011, 96, E1596-1605. 
[6] Stanhope, K. L., Havel, P. J., Endocrine and metabolic effects of consuming beverages 
sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. The American journal 
of clinical nutrition 2008, 88, 1733S-1737S. 
[7] Stanhope, K. L., Havel, P. J., Fructose consumption: potential mechanisms for its effects 
to increase visceral adiposity and induce dyslipidemia and insulin resistance. Current opinion 
in lipidology 2008, 19, 16-24. 
[8] Stanhope, K. L., Griffen, S. C., Bremer, A. A., Vink, R. G., et al., Metabolic responses to 
prolonged consumption of glucose- and fructose-sweetened beverages are not associated with 
postprandial or 24-h glucose and insulin excursions. The American journal of clinical 
nutrition 2011, 94, 112-119. 
[9] Wopereis, S., Rubingh, C. M., van Erk, M. J., Verheij, E. R., et al., Metabolic profiling of 
the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 
2009, 4, e4525. 
[10] Zhao, X., Peter, A., Fritsche, J., Elcnerova, M., et al., Changes of the plasma 
metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J 
Physiol Endocrinol Metab 2009, 296, E384-393. 
[11] Shaham, O., Wei, R., Wang, T. J., Ricciardi, C., et al., Metabolic profiling of the human 
response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 
2008, 4, 214. 
[12] Luceri, C., Caderni, G., Lodovici, M., Spagnesi, M. T., et al., Urinary excretion of 
sucrose and fructose as a predictor of sucrose intake in dietary intervention studies. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology 1996, 5, 
167-171. 
[13] Tasevska, N., Runswick, S. A., McTaggart, A., Bingham, S. A., Urinary sucrose and 
fructose as biomarkers for sugar consumption. Cancer Epidemiol Biomarkers Prev 2005, 14, 
1287-1294. 
[14] Joosen, A. M., Kuhnle, G. G., Runswick, S. A., Bingham, S. A., Urinary sucrose and 
fructose as biomarkers of sugar consumption: comparison of normal weight and obese 
volunteers. Int J Obes (Lond) 2008, 32, 1736-1740. 
[15] Tasevska, N., Runswick, S. A., Welch, A. A., McTaggart, A., Bingham, S. A., Urinary 
sugars biomarker relates better to extrinsic than to intrinsic sugars intake in a metabolic study 
with volunteers consuming their normal diet. European journal of clinical nutrition 2009, 63, 
653-659. 
[16] Tasevska, N., Urinary Sugars-A Biomarker of Total Sugars Intake. Nutrients 2015, 7, 
5816-5833. 
 25
[17] Tasevska, N., Midthune, D., Tinker, L. F., Potischman, N., et al., Use of a urinary sugars 
biomarker to assess measurement error in self-reported sugars intake in the nutrition and 
physical activity assessment study (NPAAS). Cancer Epidemiol Biomarkers Prev 2014, 23, 
2874-2883. 
[18] Freedman, L. S., Midthune, D., Carroll, R. J., Tasevska, N., et al., Using regression 
calibration equations that combine self-reported intake and biomarker measures to obtain 
unbiased estimates and more powerful tests of dietary associations. Am J Epidemiol 2011, 
174, 1238-1245. 
[19] Fave, G., Beckmann, M. E., Draper, J. H., Mathers, J. C., Measurement of dietary 
exposure: a challenging problem which may be overcome thanks to metabolomics? Genes 
Nutr 2009, 4, 135-141. 
[20] Primrose, S., Draper, J., Elsom, R., Kirkpatrick, V., et al., Metabolomics and human 
nutrition. The British journal of nutrition 2011, 105, 1277-1283. 
[21] Fave, G., Beckmann, M., Lloyd, A. J., Zhou, S., et al., Development and validation of a 
standardized protocol to monitor human dietary exposure by metabolite fingerprinting of 
urine samples. Metabolomics : Official journal of the Metabolomic Society 2011, 7, 469-484. 
[22] Lloyd, A. J., Fave, G., Beckmann, M., Lin, W., et al., Use of mass spectrometry 
fingerprinting to identify urinary metabolites after consumption of specific foods. The 
American journal of clinical nutrition 2011, 94, 981-991. 
[23] Lloyd, A. J., Beckmann, M., Fave, G., Mathers, J. C., Draper, J., Proline betaine and its 
biotransformation products in fasting urine samples are potential biomarkers of habitual 
citrus fruit consumption. The British journal of nutrition 2011, 106, 812-824. 
[24] Agency, F. S., McCance and Widdowson's The Composition of Foods, Royal Society of 
Chemistry, Cambridge 2002. 
[25] Enot, D. P., Lin, W., Beckmann, M., Parker, D., et al., Preprocessing, classification 
modeling and feature selection using flow injection electrospray mass spectrometry 
metabolite fingerprint data. Nature Protocols 2008, 3, 446-470. 
[26] Lloyd, A. J., Beckmann, M., Haldar, S., Seal, C., et al., Data-driven strategy for the 
discovery of potential urinary biomarkers of habitual dietary exposure. Am J Clin Nutr 2013, 
97, 377-389. 
[27] Hummel, J., Strehmel, N., Selbig, J., Walther, D., Kopka, J., Decision tree supported 
substructure prediction of metabolites from GC-MS profiles. Metabolomics 2010, 6, 322-333. 
[28] Stanhope, K. L., Havel, P. J., Fructose consumption: considerations for future research 
on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans. The 
Journal of nutrition 2009, 139, 1236S-1241S. 
[29] Le, M. T., Frye, R. F., Rivard, C. J., Cheng, J., et al., Effects of high-fructose corn syrup 
and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic 
responses in healthy subjects. Metabolism 2012, 61, 641-651. 
[30] Deane, N., Smith, H. W., Fate of inulin and sucrose in normal subjects as determined by 
a urine reinfusion technique. The Journal of clinical investigation 1955, 34, 681-684. 
[31] Davidek, T., Robert, F., Devaud, S., Vera, F. A., Blank, I., Sugar fragmentation in the 
maillard reaction cascade: formation of short-chain carboxylic acids by a new oxidative 
alpha-dicarbonyl cleavage pathway. Journal of agricultural and food chemistry 2006, 54, 
6677-6684. 
[32] Engelke, U. F., Zijlstra, F. S., Mochel, F., Valayannopoulos, V., et al., Mitochondrial 
involvement and erythronic acid as a novel biomarker in transaldolase deficiency. Biochimica 
et biophysica acta 2010, 1802, 1028-1035. 
[33] Rubio-Aliaga, I., De Roos, B., Duthie, S. J., Crosley, L. K., et al., Metabolomics of 
prolonged fasting in humans reveals new catabolic markers. Metabolomics 2011, 7, 375-387. 
 
